Drug Profile
Sumatriptan intranasal - Tonix Pharmaceuticals Holding Corp
Alternative Names: DFN-02; DFP 02; Sumatriptan nasal spray - Tonix Pharmaceuticals Holding Corp; TosymraLatest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator Dr Reddys Laboratories
- Developer Upsher-Smith
- Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Migraine
Most Recent Events
- 03 Jul 2023 Tonix Pharmaceuticals Holding Corp acquires sumatriptan intranasal from Upsher-Smith
- 03 Jul 2023 Tonix Pharmaceuticals has patent protection for Sumatriptan intranasal in unspecified locations
- 14 Sep 2021 Sumatriptan intranasal label carries black box warning of heart attack and other cardiovascular disorders